ライフサイエンスコーパス: nasal discharge

1 treatment group and the presence of colored nasal discharge).

2 se/ocular chlamydial positivity and positive nasal discharge.

3 e 1128 children participating, 188 (17%) had nasal discharge.

4 ed from several domestic cats with bilateral nasal discharge.

5 d its effects did not depend on the color of nasal discharge.

6 erial culture and by the presence of colored nasal discharge.

7 s of cough (2.1 vs. 5.0 days; P < .0001) and nasal discharge (3.0 vs. 4.5 days, P = .02) Blinding of

8 to 4.1] vs. 6.3 [CI, 4.9 to 7.7] days), and nasal discharge (4.1 [CI, 3.3 to 4.9] vs. 5.8 [CI, 4.3 t

9 Among 188 children with nasal discharge, 64 (34%) nasal swabs were PCR positive.

10 cR), peak nasal inspiratory flow (PNIF), and nasal discharge amount.

11 ween Chlamydia trachomatis Amplicor-positive nasal discharge and Amplicor-positive ocular swabs was i

12 Clinically, inoculated pigs had nasal discharge and fever and shed virus through nasal s

13 els at a ratio of 1:2 (infected:vaccinated); nasal discharge and virus titres were monitored for 14 d

14 ted red deer had lethargy, ocular signs, and nasal discharge and were euthanatized within 48 h.

15 oms after vaccination were nasal stuffiness, nasal discharge, and sneezing.

16 1; 95% confidence interval [CI], 1.14-4.67), nasal discharge (aOR, 4.57; 95% CI, 1.30-16.10), and str

17 than were children without Amplicor-positive nasal discharge at baseline (95% CI: 1.54-17.23), after

18 Children with positive nasal discharge at baseline were 5.2 times more likely t

19 Nasal discharge from 161 individuals, ranging from cogni

20 to a plastic toy fomite soaked with infected nasal discharge from the treatment calves.

21 Children with visible nasal discharge had swabs taken of this material.

22 clothes and back to the eye; alternatively, nasal discharge may be an indicator of severe persistent

23 Nasal discharge may provide a source of reinfection with

24 Subjective symptom scores for sore throat, nasal discharge, nasal congestion, sneezing, cough, scra

25 A history of fever, a history of cough, and nasal discharge noted on examination were each associate

26 r more than 10 days, high fever and purulent nasal discharge or facial pain lasting for at least 3 co

27 s of high fever (>39 degrees C) and purulent nasal discharge or facial pain lasting for at least 3 co

28 arge (OR 0.40, 95% CI 0.31-0.49) and lack of nasal discharge (OR 0.56, 95% CI 0.37-0.76).

29 arge (OR 0.42, 95% CI 0.23-0.61) and lack of nasal discharge (OR 0.62, 95% CI 0.52-0.72).

30 , the vaccination reduced virus shedding and nasal discharge (p = 0.0059 and p = 0.0274, respectively

31 vs -1.70 [95% CI, -2.38 to -1.03] for clear nasal discharge; P = .52 for the interaction between tre

32 , runny nose), HEENT findings on exam (i.e., nasal discharge, red throat), and having a flush toilet

33 gh, runny nose), HEENT findings on exam (ie, nasal discharge, red throat), and having a flush toilet

34 infection to severe weight loss, ocular and nasal discharge, sneezing, and lethargy.

35 exercise test was positive accompanied with nasal discharge, sneezing, throat discomfort, swelling o

36 Ipratropium recipients had 26% less nasal discharge than controls (P = 0.0024) and 34% less

37 The third year was better with sneezing and nasal discharge than the 2nd year, and the 2nd year was

38 arge than controls (P = 0.0024) and 34% less nasal discharge than untreated patients (P = 0.0001).

39 times more likely to have Amplicor-positive nasal discharge than were children without ocular positi

40 s -1.62 [95% CI, -2.09 to -1.16] for colored nasal discharge vs -1.70 [95% CI, -2.38 to -1.03] for cl

41 r significantly according to whether colored nasal discharge was present (the between-group differenc

42 to characterize the associations of IAD and nasal discharge with viral and bacterial infections.